@prefix orcid: <https://orcid.org/> .
@prefix this: <http://purl.org/np/RAiifmEOA6wAXFb3IOYgEhuRNuiKuALUBT-FxiUhEgse0> .
@prefix sub: <http://purl.org/np/RAiifmEOA6wAXFb3IOYgEhuRNuiKuALUBT-FxiUhEgse0#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/triples/select?fl=TRIPLE_UID,%20CORD_UID,%20SUBJECT,%20PREDICATE,%20WORDNET_SEMREL,%20%20OBJECT,%20PRED_POSITION,%20SUBJECT_CUIS,%20OBJECT_CUIS,%20UMLS_SEMREL,%20PRED_POSITION,%20PREDICATE-LEMMA&q=CORD_UID:6bnj8pcp&rows=> .
@prefix ns1: <http://wordnet-rdf.princeton.edu/lemma/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=TRIPLE_UID:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  <https://uts.nlm.nih.gov/uts/umls/concept/C1512714> ns1:compare <https://uts.nlm.nih.gov/uts/umls/concept/C1144149> .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-12-16T19:34:14.353772"^^xsd:dateTime;
    prov:wasGeneratedBy "S&T TWOC project version 2" .
  
  sub:version prov:value "2"^^xsd:integer .
  
  rdf:OBJECT rdfs:label "with lenalidomide and dexamethasone alone ( Rd )" .
  
  rdf:OBJECT-POSITION rdfs:label "4"^^xsd:integer .
  
  rdf:PREDICATE rdfs:label "compared" .
  
  rdf:PREDICATE-POSITION rdfs:label "[221]" .
  
  rdf:SUBJECT rdfs:label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" .
  
  rdf:SUBJECT-POSITION rdfs:label "102"^^xsd:integer .
  
  rdfs:ABSTRACT-UID ns2:50 "6bnj8pcp" .
  
  rdfs:SENTENCE rdfs:label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." .
  
  rdfs:TRIPLE-UID ns3:6bnj8pcp-TRIPLE-ABSTRACT-5 "6bnj8pcp-TRIPLE-ABSTRACT-5" .
  
  <https://uts.nlm.nih.gov/uts/umls/concept/C1144149> rdfs:label "lenalidomide" .
  
  <https://uts.nlm.nih.gov/uts/umls/concept/C1512714> rdfs:label "ineligible" .
}

sub:pubInfo {
  sub:assertion prov:wasDerivedFrom <https://doi.org/10.1200/jco.20.01849> .
  
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
    npx:hasSignature "WXGUJrwD+ZMvbxvCrElV5CQbGSP7UdV3vOlYTN4I7t1LrsS8foOC3zstwbwlAmK+OTE2aC3VWWsQYx9VHXaRemzWsToW2lpc4ap6syWu4r/702C0PRvQwsfQE4t5pLXu0Bf53v3ZwOGwO5bHrV/RhM7A+p0tEQLPBanAEBIm2YU=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-12-16T19:34:14.353772"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}